KRAS and colorectal carcinoma: In summary, these data suggest that decreasing GTP production by overexpressing SLC25A21 to reduce the available raw material for the conversion of α-KG to succinate and/or inhibiting SCS activity inhibits KRAS activity, which may be a potential treatment strategy for CRC patients with KRAS mutations.